<DOC>
	<DOCNO>NCT00936585</DOCNO>
	<brief_summary>The objective NIH-specific substudy immunologic monitoring cytokine immune cell responses subject undergoing treatment AIN457 ( human monoclonal anti-human interleukin-17A ) moderate severe Crohn 's disease . Recent data suggests interleukin-17 ( IL-17 ) important mediator inflammation certain animal model Crohn 's disease , treatment aim block IL-23-IL-17 axis ameliorate inflammatory change . In addition , elevated expression IL-l7 find gut tissue patient active Crohn 's disease . This substudy measure change cytokine production , relevant RNA expression , immune cell population ( periphery lamina propria ) correlation clinical outcome order explore mechanisms therapeutic response .</brief_summary>
	<brief_title>NIH Substudy AIN457 ( Anti-IL-17 Monoclonal Antibody ) Treatment Moderate Severe Crohn 's Disease</brief_title>
	<detailed_description>Purpose : - Crohn 's disease inflammatory bowel disease major symptom diarrhea abdominal pain disease active stage . - AIN457 protein develop NOVARTIS use stop action Interleukin-17 ( IL-17 ) , protein make body contributes many different kind inflammatory disease , include Crohn 's disease . AIN457 develop potential treatment various inflammatory disease like rheumatoid arthritis psoriasis , test suitability people Crohn 's disease . Objectives : - The main objective NIH substudy obtain additional blood gut biopsy tissue monitor biochemical change immune variable response study drug placebo . - The main objective main multicenter study ( sponsor NOVARTIS ) determine whether AIN457 safe effective treatment Crohn 's disease , effective , long effect remain . Eligibility : - Important eligibility criterion consider patient enrol AIN457 trial include : Inclusion criterion : - Male female ; 18-75 year old - Diagnosis Crohn 's disease least 3 month prior screen - Moderate severe active Crohn 's disease baseline , define : CDAI great equal 220 less equal 450 - Active disease despite prior treatment stable dose corticosteroid 2 week , immunosuppressant least 3 month ( e.g . methotrexate , azathioprine ) . Exclusion criterion : - Subjects symptoms associate active bowel stricturing disease pre-stenotic dilation radiography . - Fistulizing disease complicate sepsis and/or untreated abscess . - Subjects multiple bowel surgery clinically important short bowel syndrome define inability maintain caloric intake . - Prior therapy rituximab . - Receiving corticosteroid dose equivalent &gt; 40mg dose prednisone per day . - Subjects demonstrate clinical improvement due Crohn 's therapy . - Subjects active history clinically significant cardiac abnormality . Design : - For NIH substudy , additional blood drawn colonoscopy perform first infusion second infusion . - The multicenter study plan enroll seventy-two ( 72 ) subject moderate severe active Crohn 's disease control corticosteroid , immunosuppressant ( e.g . methotrexate purine metabolite ) anti-inflammatory treatment ( e.g . 5-ASA ) . At baseline visit , eligibility subject confirm , subject randomize ( 2:1 ratio ) receive either AIN457 placebo administer 2 hour intravenous infusion . A total two infusion give day 1 day 22 respectively . - After infusion follow-up period 18 week . - Once study complete , extension study conduct offer access AIN457 . Patients complete current study may eligible enter extension study receive therapy AIN457 .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Male female ; 1875 year old 2 . All female subject must negative pregnancy test result screen baseline . Women childbearing potential ( WoCBP ) must use simultaneously doublebarrier two acceptable method contraception , ( e.g. , intrauterine device plus condom , spermicidal gel plus condom , diaphragm plus condom , etc . Hormone replacement either oral implantable acceptable one form ) , time screen duration study , study completion 4 month follow study completion . Periodic abstinence ( e.g . calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception . Postmenopausal females must regular menstrual bleeding least two ( 2 ) year prior initial dosing . Menopause confirm serum FSH level &gt; 40 IU/L screening . Pregnancy test require screening . Female subject report surgical sterilization must procedure least six ( 6 ) month prior initial dosing . Surgical sterilization procedure support clinical documentation make available sponsor note Relevant Medical History/Current Medical Conditions section CRF . If female subject male partner undergone vasectomy , vasectomy must occur six ( 6 ) month prior first dose . 3 . Male subject willing use simultaneously two acceptable method contraception ( e.g . spermicidal gel plus condom ) entire duration study , study completion visit least 6 month follow completion study . Periodic abstinence withdrawal acceptable method contraception . 4 . Diagnosis Crohn 's disease least 3 month prior screen 5 . Confirmation Crohn 's disease endoscopic image examination 6 . Moderate severe active Crohn 's disease baseline , define : CDAI great equal 220 less equal 450 7 . Patients active disease despite prior treatment corticosteroid least 2 week , immunosuppressant least 3 month . Patients treated azathioprine , 6MP MTX eligible must stable dose least 10 week prior baseline . Patients treat corticosteroid eligible must stable dos prednisolone exceed 40 mg two week prior baseline . Patients treat immunosuppressant list , cyclosporine , tacrolimus mycophenolate , eligible . These subject require stop immunosuppressant prior baseline . These patient eligible observe wash period specify Exclusion criterion # 7 . 8 . Absence clinically relevant abnormality screen laboratory test result 9 . Able communicate well investigator , understand comply requirement study . 10 . Understand sign write informed consent . EXCLUSION CRITERIA : Subjects meet follow criterion exclude entry continuation study , unless sponsor approval obtain : 1 . Body Mass Index great 34 . 2 . Positive Purified Protein Derivative ( PPD ) tuberculin skin test great equal 5 mm screen 6 month prior screen . A positive PPD test define use [ MMWR 2000 guidance ] , summarize criterion tuberculin positivity risk group . A PPD test do subject tuberculosis vaccination past . These subject eligible participate , accord local guideline , latent tuberculosis exclude . For study site use QuantiFeron test positive test screen exclude subject participation study . If result either PPD QuantiFeron test indeterminate , subject exclude . 3 . Subjects symptoms associate active bowel stricturing disease prestenotic dilation radiograph . 4 . Fistulizing disease complicate sepsis and/or untreated abscess . 5 . Subjects multiple bowel surgery clinically important short bowel syndrome define inability maintain caloric intake . 6. a. Concomitant treatment antiTNFalpha therapy ( biological therapy ) systemic immunosuppressive agent cyclosporine , mycophenolate , pimecrolimus , tacrolimus , except azathioprine , metabolite 6MP MTX . The follow washout period require subject eligible participate trial . Three ( 3 ) month washout prior baseline certolizumab Two ( 2 ) month washout prior baseline adalimumab , etanercept infliximab One ( 1 ) month washout prior baseline cyclosporine , mycophenolate , pimecrolimus , tacrolimus , systemic immunosuppressant list exclusion criterion # 7b 6b . Patients treated azathioprine , 6MP MTX eligible must stable dose least 10 week prior baseline throughout whole study period . 7 . Prior therapy rituximab . 8 . Receiving corticosteroid dose equivalent great 40mg dose prednisone per day . 9 . Subjects demonstrate clinical improvement due Crohn 's therapy . 10 . Current sign symptom severe , progressive , uncontrolled renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , cardiac , neurologic , cerebral , psychiatric , disease would make subject unsuitable trial . 11 . Subjects active history clinically significant cardiac abnormality , example : Requiring drug QTprolonging property ( e.g . antiarrhythmic drug , amiodarone , sotalol , dofetilide , quinidine , procainamide , disopyramide ) . QTc great 450msec long QTsyndrome ( family history ) family history sudden unexplained death . Left branch bundle block ( LBBB ) , subject hospitalize heart failure cardiac etiology , previous 6 month , subject significant persistent leftventricular dysfunction ( LVEF less 40 % ) . History precede 3 month , significant persistent arrhythmia ventricular fibrillation tachycardia , atrial fibrillation flutter . Symptomatic coronary artery disease . Presence severe cardiac disease ( New York Heart Association Classification great equal III ) and/or abnormal ECG , consider investigator unsafe study . 12 . Liver disease liver injury indicate abnormal liver function test SGOT ( AST ) , SGPT ( ALT ) , gammaGGT , alkaline phosphatase , serum bilirubin . The Investigator guide follow criterion : Any single parameter may exceed 2 time upper limit normal ( ULN ) . A single parameter elevate include 2 time ULN rechecked soon possible , case , least prior enrollment/randomization , rule lab error . If total bilirubin concentration increase 2 time ULN , total bilirubin differentiate direct indirect react bilirubin . In case , serum bilirubin exceed value 1.6 mg/dL ( 27 micromol/L ) . Recheck result must within normal limit ( return within normal limit ) order subject qualify . 13 . Total WBC count fall outside range 450013,000/microL , platelet le 100,000/microL screening . 14 . History severe hypersensitivity biological agent ( antibody soluble receptor ) , include serious allergic reaction ( hypotension , wheeze , urticaria ) , lupuslike syndrome demyelinate disease . 15 . Donation loss 400 mL blood within 8 week prior dose longer required local regulation . 16 . Administration live vaccine within 6month prior dosing . 17 . History immunodeficiency disease , include positive HIV ( ELISA Western blot ) test result . 18 . A positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result . 19 . Significant illness within two week prior dose active systemic infection medical condition may require treatment therapeutic intervention study . 20 . Subjects : History presence impair renal function indicate clinically significantly abnormal creatinine great 1.3 mg/dL blood urea nitrogen ( BUN ) great 30 mg/dL , presence great +1 albumin urinary dipstick . Presence proteinuria , active sediment , cast WBCs urine . Evidence urinary obstruction difficulty void screen . History renal trauma , glomerulonephritis , subject one kidney . 21 . History malignancy ( basal cell carcinoma adequately treat carcinomainsitu cervix ) . 22 . Unable unwilling undergo multiple venipuncture poor tolerability lack easy access vein . 23 . Conditions associate immunecompromised condition recent surgical procedure ; history drug alcohol abuse within 12 month prior dose . Subjects unable discontinue analgesic medication contain opiate opioids , well cannabinoids medical use . 24 . Participation clinical investigation within four ( 4 ) week prior initial dose five halflives investigational agent , whichever longer , limitation participation base local regulation . NIH EXCLUSION CRITERIA : 1 . Platelet count le 100,000 mm ( 3 ) 2 . Prothrombin Time International Normalized ration ( PT INR ) great 1.3 Partial Thromboplastin Time ( PTT ) 3 sec control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>Infusion</keyword>
	<keyword>Anti IL-17 Monoclonal Antibody</keyword>
	<keyword>Placebo</keyword>
	<keyword>Crohn Disease</keyword>
	<keyword>Inflammatory Bowel Disease</keyword>
</DOC>